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Objective  To evaluate the efﬁ  cacy of 
pancrealipase (PEZ) compared with placebo 
in the reduction of postprandial irritable 
bowel syndrome-diarrhoea (IBS-D).
Design  An intention to treat, double blind, 
randomised, crossover trial comparing PEZ to 
placebo for reduction of postprandial IBS-D. 
Patients had to recognise at least two different 
triggering foods, be willing to consume six 
baseline ‘trigger meals’ and again blinded with 
PEZ and placebo. Patients then chose which 
drug they preferred for another 25 meals.
Setting Outpatient  internal 
medicine practice clinic.
Patients  255 patients were screened; 
83 met the criteria, including 5 years of 
symptoms, recognised ‘food triggers’, no 
other identiﬁ  able cause for the symptoms, 
either a normal colonoscopy or barium enema 
while symptomatic and able to discontinue all 
anticholinergic medications. 69 patients were 
enrolled, 20 withdrew before randomisation, 
leaving 49 patients: 14 men, 35 women, 
mean age 52 years (SD 15.3). Over 60% 
had experienced symptoms for 11–30 
years and 16% for more than 40 years.
Interventions  After completing six 
baseline meals, patients were randomised 
in blocks of four to receive either 
identical PEZ or a placebo for another 
six meals, and after a washout period of 
time received the alternative drug.
Main outcome measures The  primary 
analysis was number of patients who chose 
PEZ over placebo for the extended use.
Results  Overall, 30/49 (61%) would have 
chosen PEZ (p=0.078), with ﬁ  rst drug 
preference for PEZ at 0.002. Among the PEZ 
subgroup, PEZ use compared with placebo, 
demonstrated improvement in all symptoms 
(p≤0.001) for cramping, bloating, borborygami, 
urge to defecate, global pain and decrease 
stooling with increase in stool ﬁ  rmness.
Conclusions  PEZ was found in a small group 
of patients to reduce postprandial IBS-D 
symptoms and deserves further evaluation.
Introduction
At the current time, a large number of 
individuals are experiencing major gastro-
intestinal complaints after consuming cer-
tain foods, liquids, spices, etc. If diarrhoea 
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Pilot study: a randomised, double blind, 
placebo controlled trial of pancrealipase for 
the treatment of postprandial irritable bowel 
syndrome-diarrhoea
Mary E Money,1,2 Jaroslaw Walkowiak,3 Chris Virgilio,1,4 Nicholas J Talley5,6
What is already known about this 
subject?
  The irritable bowel syndrome affects close to    ▶
15% of the population and approximately 
one-third of these individuals have the 
diarrhoea condition.
  The diagnosis is made on the Rome III    ▶
symptom criteria which have not been 
validated to exclude organic disease.
  The Rome III criteria do not include what    ▶
precedes the diarrhoea as being important 
although 50–75% of individuals recognise that 
the diarrhoea occurs after eating.
  Treatment recommendations for the irritable    ▶
bowel syndrome-diarrhoea condition do not 
routinely include pancrelipase.
What are the new ﬁ  ndings?
  A subgroup of patients with irritable bowel    ▶
syndrome-diarrhoea responded with a 
reduction of their postmeal symptoms by the 
ingestion of pancrelipase before eating.
How might they impact on clinical 
practice in the foreseeable future?
      This study may increase the recognition that    ▶
these patients may have a form of maldiges-
tion which can be improved by the supple-
mentation of pancrelipase before consuming a 
meal or known ‘trigger’.
      Further research may be stimulated by this    ▶
pilot study.
This paper is freely available 
online under the BMJ Journals 
unlocked scheme, see http://
fg.bmj.com/info/unlocked.dtl
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is present, complaints are typically diagnosed as either 
functional diarrhoea (if without pain) or the ‘irritable 
bowel syndrome-diarrhoea’ (IBS-D), if pain is present 
with the episode.1–5 IBS is a condition affecting an esti-
mated 10–15% of the US population.6 7 Although not 
included in the widely accepted Rome criteria for IBS,7 8 
theories for why the symptoms occur after eating have 
included the following: food intolerance, food aller-
gies or hypersensitivity, an alteration of bowel bacteria 
or psychosocial factors.9–11
A maldigestion or malabsorption problem is not usu-
ally considered if the food product is not related to lac-
tose. However, a recent study conducted by Shepherd 
suggested that fructose malabsorption contributed to 
some of these complaints.12 A low α-glucosidase activ-
ity has been recognised as the cause of chronic osmotic 
diarrhoea in 21% of children diagnosed with recurrent 
abdominal pain associated with diarrhoea,12a and has 
also been recognised in adults.13–15 The diagnosis of a 
disaccharidase deficiency which clinically causes diar-
rhoea after eating is only made after the objective find-
ing of a deficiency in the concentration of the enzymes 
in the brush border of the small intestine or the pres-
ence of a high osmotic gap in stool water that has a pH 
<5. These tests are not usually performed on patients 
who meet the criteria for IBS-D.
Mainstream treatment recommendations for IBS-D, 
other than dietary modifications, have predominantly 
been antidiarrhoeal agents such as loperamide and 
diphenoxylate, tricyclic antidepressants or aloset-
ron, a 5HT3 receptor antagonist.7 16–18 Other possible 
therapies have included clonidine,19 cholestyramine,18 
Chinese herbal therapy,20 21 cromolyn22 23 and psycho-
therapy.24 25 Antispasmodic agents such as hyoscyamine 
and dicyclomine are often prescribed but have not 
been established to be beneficial and may lose any pos-
sible benefit over time.7 Pancrealipase (PEZ) has been 
shown to reduce bile acid malabsorption in patients 
with cystic fibrosis,26–28 chronic pancreatitis,29 fat mal-
absorption due to HIV30 and improve digestion in 
normal patients consuming a fatty meal.31 PEZ has 
recently been reported as being effective for the post-
prandial IBS-D condition32 and among patients identi-
fied with pancreatic insufficiency who also have IBS.33 
α-Amylase, a major component of PEZ, has been 
shown to augment disaccharidase activity.34 35
We hypothesised that some symptoms of IBS are due 
to maldigestion and/or malabsorption of certain foods. 
We therefore aimed to test the effectiveness of PEZ 
compared with placebo in the reduction of the symp-
toms in patients who have IBS-D after eating known 
triggering agents.
Methods
Patients
Patients were recruited by referral from local physicians 
and advertisements. Strict eligibility and exclusion cri-
teria were used to establish the patient group including: 
18 years or older; at least 5 years of only IBS-D symp-
toms before age 50 years, at least 12 times annually 
which had to occur within 3 h of eating at least two 
different triggering foods (specific for each patient); 
and onset before a cholecystectomy. Intolerance only 
to milk products was not acceptable. Patients were not 
eligible if they had unexplained weight loss, felt symp-
toms were due to medication or had been diagnosed 
with other gastrointestinal disorders which might 
explain the symptoms. A normal colonoscopy or a 
barium enema was required to have been completed 
while having postprandial symptoms. Discontinuation 
of gastrointestinal anticholinergic agents prior to 
enrolment was required and was not permitted to be 
restarted. Antidepressant use was allowed and any new 
treatments, drug therapies or dosage changes were 
recorded. Antidiarrhoeal drugs were permitted only 
after postprandial symptoms started and not before a 
meal. In total, 49 patients were randomised into the 
study (see results section below).
All patients entered into the study met the Rome II cri-
teria for IBS: 12 consecutive or non-consecutive weeks 
or more in the past 12 months of abdominal discomfort 
or pain with two of the three features of (1) relief with 
defecation, (2) onset associated with a change in stool 
frequency and/or (3) onset associated with a change in 
the form (appearance) of the stool.24 36 37
In this study, patients were restricted to having only 
postprandial IBS-D.
Study design
An original rigorous study design was created in an 
attempt to demonstrate PEZ effectiveness over pla-
cebo when taken by IBS-D patients before consuming 
a triggering agent. This study followed a randomised, 
double blind, placebo controlled, crossover design with 
patients serving as their own controls. It was felt that a 
parallel group study design would require more enroll-
ees (see power calculation below).  The study was not 
designed to evaluate for bacterial overgrowth or the 
presence of malabsorption due to limited funding.
Each patient was required to record the severity of 
specific postprandial symptoms that occurred after 
each trigger meal: cramping, bloating, borborygami, 
nausea, intensity to have a bowel movement, other 
symptoms of sweating/chills and global pain from 0 to 
10. Time of onset, duration of the episode along with 
stool frequency and consistency were also recorded 
on a specially designed meal diarrhoea form. Stool 
consistency was scored in a graduated fashion from 
normal (2 points) to watery diarrhoea (10 points) 
(table 1).
The meal list for patients was as follows: one non-
trigger meal with a food not recognised to precipitate 
IBS symptoms; six baseline trigger meals with patient 
specific known trigger foods; 4–12 trigger meals with 
drug 1 (blinded: PEZ or identical placebo); another 
4–12 trigger meals with drug 2 (blinded: PEZ or 
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identical placebo); and 25–50 meals using their prefer-
ence (drug 1 or 2 for all meals).
Each patient was permitted to return to their prior 
treatment or take PEZ after they completed the study. 
An open label follow-up was conducted 3 months 
after the study ended. An IBS-Specific Quality of Life 
(QOL) Health Questionnaire (IBS-QOL), used with 
permission from Patrick et al,38 was completed by each 
patient at enrolment, completion and 3 months later 
during the open label follow-up.
Randomisation and concealed allocation
Only after completion of six baseline trigger meals was 
each participant enrolled by the study investigator and 
was randomised according to a computer generated 
blocked randomisation list using a block size of four to 
receive as either the first or second drug: PEZ (Viokase: 
lipase 8000; amylase 30  000; and protease 30  000; 
Axcan Pharma, Quebec, Canada) or placebo capsule 
(Cebocaps Blue, size 1 from Forest Pharmaceuticals 
(New York City, New York, USA) containing inert 
sucrose, starch, acacia, talc, gelatin and artificial col-
our). Randomisation of patients and concealed alloca-
tion were assured by the trial pharmacist who prepared 
the drug vials which were numbered sequentially.
Blinding and dosing
Both drugs were placed inside a second dark coloured 
space capsule, size 0. Therefore, both drugs were iden-
tical by weight and size with no perceivable taste dif-
ference. Patients were given 12 capsules for each drug 
period and were instructed not to open them. Patients 
were permitted to titrate the dose from 1 to 3 capsules 
before each meal, and therefore could potentially con-
sume up to 12 meals prior to receiving the next drug if 
one capsule was effective. This dosage was determined 
based on the clinical experience of the investigators 
of effective dosage of PEZ among IBS-D patients cur-
rently taking PEZ. After the first drug was used for at 
least four meals, patients received the alternate drug. A 
minimum 1 week washout period between drugs was 
required. Patients were instructed and encouraged to 
try to consume the same trigger meals for each drug 
but were not excluded from the study if they failed to 
meet this requirement. Once both drugs were tried, 
the patients then chose which of the two drugs (still 
blinded) they wanted to use for a prolonged period of 
up to 50 trigger meals (their choice of meals). There 
was no time pressure for completion of the meals at 
any phase of the study. Patients were also permitted to 
use antidiarrhoeal agents as needed for breakthrough 
diarrhoea.
Follow-up period
Follow-up by study personnel occurred at completion 
of the baseline meals, after each drug use, at meal 25 
of extended use and after consumption of meal 50. At 
every visit, each participant was interviewed for proto-
col adherence, including their attempt at duplication of 
baseline meals for drug 1 and drug 2, side effects and 
changes in other medical conditions or medications. 
Patients and investigators were unaware of the drug 
sequences or choice of drug for the final use until the 
entire trial had been concluded. Each patient, on study 
completion, could contact the trial pharmacist who 
Table 1  Subjective and objective symptoms scoring for each meal
Symptoms Subjective point score
 Cramping 0–10
 Bloating 0–10
 Borborygami 0–10
 Nausea 0–10
  Urge to have a bowel movement 0–10
 Sweating,  chills 0–10
  Global abdominal pain 0–10
No of bowel movements 1 point each bowel movement
Consistency of each stool Subjective point score
 Normal 2
 Soft 4
  Mushy, not formed 6
  Loose, no water 8
 Watery  diarrhoea 10
Onset and duration of symptoms
Time period Onset points Duration points
 0–30  min 10 2
 31–60 8 4
 61–90 6 6
 91–120 4 8
 >121 2 10
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was permitted to disclose to the patient his/her final 
choice. Therefore, patients could obtain a prescription 
for PEZ before the conclusion of the trial from their 
personal physician, if desired. A 3 month follow-up 
was also done after completion of the study.
The Washington County Hospital Institutional 
Review Board approved the study and each participant 
gave written informed consent. Patients could with-
draw from the study at any time or be removed for 
study protocol violations. The trial was approved by 
the Washington County Hospital Institutional Review 
Board on 18 January 2002. Enrolment was completed 
with 49 patients. The study concluded on 4 November 
2003.
Statistical analysis
The primary analysis was the effectiveness of PEZ 
compared with placebo in reduction of postprandial 
symptoms among the number of individuals who chose 
the enzymes as the effective agent for the prolonged 
use period. A one way χ2 test was used for final analy-
sis of the number of individuals who chose placebo 
versus PEZ as the effective drug (primary end point) 
by intention to treat analysis. Independent sample 
t tests and two way χ2 tests were used to determine 
any difference among subgroups for age, sex, number 
of years for IBS-D, positive family history of a similar 
problem, length of time for completion of the study, 
frequency of episodes and comparison of effectiveness 
of their choice of agents. One way χ2 tests were also 
used to subanalyse both final groups (selected PEZ or 
placebo) for determining the effectiveness of the drugs 
compared with baseline average meal scores, enzyme 
meals, placebo meals and second use of the ‘choice 
drug’. Average meal scores for each person were cal-
culated by adding all of the symptom scores for all 
meals in that section and then dividing by 6 (the total 
number of meals).
Patient scores were not used if they consumed 
fewer than six meals in each section for comparison. 
Individual symptom scores for bloating, nausea, bor-
borygami, cramping, urge for defecation, sweating/
chills and number of bowel movements were individu-
ally analysed by one way χ2 tests for the enzyme sub-
group comparing enzyme therapy with placebo.
The t test was used for analysis of the QOL meas-
urements before and at the conclusion of the study 
for this subgroup, and for those patients who were 
on enzymes at the 3 month follow-up. All p values 
calculated were two tailed; the α level of significance 
was set at 0.05.
Power calculation
Based on an estimated mean total symptom score of 
100 in the placebo group with an SD of 50, it was 
estimated that approximately 35 patients would be 
needed to provide 80% power to detect a 50% change 
in symptoms between the drug treatments (PEZ and 
placebo).
Results
Participants
A total of 255 patients were screened for the study 
and 83 met the IBS-D criteria (ineligible patients 
included those who did not meet the Rome II cri-
teria; had not had a colonoscopy or barium enema; 
had constipation IBS; did not know their specific 
triggering foods; and had previously been diagnosed 
with a medical condition causing the diarrhoea, such 
as inflammatory bowel disease). Of the 83 eligible 
patients, 69 were enrolled, but after reviewing the 
study requirements, 20 withdrew before being ran-
domised. Thus 49 patients were randomised into the 
study (figure 1).
Patient characteristics were as follows: 14 men, 
35 women, mean age 52 years (SD 15.3); 74% had 
symptom onset before the age of 30 years; over 60% 
had experienced symptoms for 11–30 years; and 
16% had experienced them for more than 40 years. 
Thirteen patients identified anxiety or depression as a 
current comorbid condition, and eight were using an 
antidepressant (paroxetine (n=3), fluoxetine (n=1), 
sertraline (n=1), desipramine (n=1), venlafaxine 
(n=1) and amitriptyline (n=1)). Two patients were 
using lorazepam or alprazolam. Eight of the patients 
had onset of IBS symptoms at least 5 years prior to 
a cholecystectomy. Prior medications used by patients 
included: loperamide (n=30), fibre supplement 
(n=22), antidepressants (n=9) and anticholinergics 
(n=15). Prior negative studies included colonoscopy 
(n=42), barium enema (n=26), upper gastrointestinal 
examination with small bowel follow through (n=8), 
oesophagogastroduodenoscopy (n=10) and pancreatic 
function studies (n=4).
Although not a requirement for participation, 30 
patients participated in additional testing for evalua-
tion of pancreatic insufficiency and presence of coeliac 
disease. Testing for malabsorption, serum IgA levels 
and antibodies to coeliac disease was completed by one 
of the authors (JW at the Poznań University of Medical 
Sciences, Poznań, Poland). All participants had normal 
endomysium and tissue transglutaminase antigens val-
ues for coeliac disease39 40; 47 serum lipase measure-
ments were evaluated and only three were less than 
10% above normal (10–60 U/l).41 There were 29 meas-
urements for IgA g/l; only two were slightly elevated 
and none was low (normal 0.7–4.0 g/l). Of the 60 stool 
specimens tested for faecal elastase 1, only four regis-
tered values less than 200 µg/g faeces, the lowest being 
112 µg/g.42 Three of the four patients who had abnor-
mally low faecal elastase selected the placebo as the 
‘effective agent’.
Each participant identified an average of 12 trig-
gering foods, ranging from 2 to 23. Common food/
spice triggers included: spicy seasoning (78%), let-
tuce (particularly iceberg) (71%), Italian food (69%), 
milk based products (69%), cabbage (67%), Chinese 
food (61%), fried food (59%), barbecue spices (49%), 
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hot peppers (46%), green peppers (41%), tomatoes 
(45%), onions (43%), apple (37%), eggs (35%), 
orange juice (31%), soy sauce (31%), beef/pork 
(29%), garlic (24%), coffee/tea (20%) and chocolate 
(14%). Eighty-eight per cent had symptoms after eat-
ing out in a restaurant.
Thirty-two (69%) of the patients reported another 
family member with the same problem: father (n=28), 
mother (n=24), sister (n=20), daughter (n=4), broth-
ers (n=3) and sons (n=3).
Choice of effective agent
Of the 39 patients who completed the study by using 
each drug for at least four trigger meals, 25 (64%) chose 
PEZ over placebo as the effective agent. Based on the 
intention to treat analysis by including those individuals 
who dropped out of the study as failures, 30/49 (61%) 
would have chosen enzymes while 19/49 (39%) would 
have selected the placebo (p=0.078). Notably, the χ2 
test for selection based on first drug administered was 
statistically significant with the first drug preference if 
PEZ were received first (p=0.002) but was not signifi-
cant if the individual received placebo first (p=0.49).
Both the placebo subgroup and the enzymes sub-
group were analysed for age, gender, family history 
of similar problems, duration and frequency of IBS-D 
episodes, and time that it took to complete the study. 
There was no statistically significant difference in any of 
the above parameters between the subgroups to reflect 
their final choice. Loperamide use in both groups was 
not statistically significant and use decreased by at least 
50% among patients in each group.
Placebo choice and patient withdrawal
Fourteen patients chose placebo over enzymes, 11 of 
whom had placebo as their first drug. Effectiveness of 
the placebo capsule was comparable to PEZ among 
those who chose the placebo.
Ten patients withdrew from the study. Two never 
completed the initial six baseline trigger meals and 
another six patients never completed the first drug 
meals: four taking placebo, two taking PEZ. Another 
two patients withdrew after trying the second drug, 
which was placebo in each case. Thus a total of six 
out of eight patients withdrew during a placebo drug 
phase.
Figure 1  Consort diagram outlining the study design.
Withdrew before randomization  N=20
  Unable to stop anticholinergic drug n=2
  Study too demanding n=13
Unable to identify specific food triggers n=5
Eligible
N=83
Signed Consents
N=69
Randomized
N=49
DRUG 1
ENZYMES
N=25
DRUG 1
PLACEBO
N=24
Placebo
N=11
Enzymes
N=8
Enzymes
N=17
Placebo
N=3
Final Choice
Placebo
N=14
Final Choice
Enzymes
N= 25
Number Patients Screened
N=255
Withdrew N=5
Baseline not
completed n=1
Never finished
drug 1 n=4
Withdrew N=3
Baseline not
completed n=1
Never finished
drug 1 n=2
DRUG 2
ENZYMES
N=19
DRUG 2
PLACEBO
N=22
Withdrew N=2
Never completed
drug 2 n=2
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Subanalysis of enzyme subgroup
Twenty-five of the 39 patients who finished the study 
(64%) chose PEZ over placebo as the effective agent. 
Seventeen had the enzymes as the first drug and eight 
were given it as the second drug. Among the enzyme 
subgroup, PEZ resulted in a mean 60.3% reduction 
of IBS-D symptoms from baseline meal scores com-
pared with a 34% change with placebo, which was 
statistically significant (p<0.001). Individual symptom 
comparison between enzymes and placebo for this sub-
group are shown in table 2.
Improvement in symptoms (p≤0.001) was identified 
for cramping, bloating, borborygami, urge to defecate 
and pain when enzymes were used in comparison 
with placebo. Likewise, the decrease in the number of 
stools and increase in stool firmness were statistically 
significant between placebo and second use of enzymes 
(p<0.001).
Compliance with trigger meal consumption and severity of 
IBS symptoms
Average scores of the six baseline trigger meals among 
all participants ranged from 35 to 127 points. These 
scores did not follow a normal distribution pattern, 
reflecting the wide range of symptoms. Twenty-seven 
of the 39 patients who completed the study (69%) fol-
lowed the study protocol and consumed identical trig-
ger meals for baseline, drug 1 and drug 2 more than 
75% of the time. There was no difference in meal 
compliance between the final choice subgroups: PEZ 
17/25 (68%), placebo 10/14 (71%).
QOL at baseline and completion of study
Table 3 shows a significant improvement in IBS-QOL 
scores (p=0.000–0.036) from baseline to completion of 
the study for the enzyme subgroup participants. A sta-
tistical comparison of IBS-QOL scores among patients 
choosing placebo versus enzymes was not possible due 
to the small sample size of the placebo subgroup.
Safety and side effects
There were no serious adverse events during the 
trial. The only side effect was increased flatus (n=2 
placebo; n=1 PEZ) and mild constipation (n=1 pla-
cebo; n=2 PEZ). One patient complained of increased 
abdominal pain and insomnia while using the placebo 
preparation.
Open label 3 month follow-up
Patients were contacted 3 months after the conclu-
sion of the trial. We located 46 (94%) patients and 
Table 2  Statistical analysis of enzymes compared with placebo for reduction of irritable bowel syndrome-diarrhoea 
symptoms in enzyme subgroup
Symptom 
(0–10 severe) Mean with placebo
Mean with PEZ 
as No 1 drug
p Value 
(PEZ as No 1 drug)
Mean with PEZ 
as choice
p Value 
(PEZ as choice)
Cramping 3.50±2.73 1.42±1.88 0.006 1.09±1.69 0.001
Bloating 2.72±1.90 1.31±1.56 0.009 0.90±1.30 0.000
Borborygami 3.25±2.07 1.90±1.95 0.006 1.37±1.62 0.001
Nausea 0.53±0.92 0.26±0.53 0.057 0.21±0.53 0.034
Urgency 4.63±2.67 2.14±2.00 0.002 1.79±1.93 0.000
No of stools 1.89±1.03 0.79±0.91 0.000 0.68±0.88 0.000
Duration attack (min) 98.94±92.76 88.54±181.81 0.898 53.47±86.45 0.072
Sweating 0.72±1.18 0.34±0.63 0.181 0.28±0.60 0.106
Stool consistency 12.00±7.12 4.19±5.24 0.000 3.55±5.50 0.000
Abdominal pain 3.64±2.70 1.45±1.83 0.003 1.14±1.88 0.000
PEZ, pancrealipase.
Table 3  Quality of life (QOL) comparison between baseline and completion of trial for 
pancreatic enzyme subgroup
Baseline Completion of trial
QOL parameter Mean N Mean t p Value
Dysphoria 45.74±28.08 22 75.71±21.97 −5.04 0.000
Interference w/activity 37.42±18.02 21 68.54±21.36 −6.14 0.000
Body image 70.07±23.35 19 86.84±15.44 −3.27 0.004
Health worry 64.68±16.65 21 82.94±13.30 −4.55 0.000
Food avoidance 20.83±20.21 22 56.06±27.96 −5.55 0.000
Social reaction 54.89±19.49 23 76.36±21.81 −4.87 0.000
Sexual 73.21±33.14 21 85.12±26.70 −2.25 0.036
Relationships 56.67±23.51 20 77.50±19.70 −5.35 0.000
Overall score 46.11±15.35 14 77.10±15.82 −5.49 0.000
11_flgastro2253.indd   53 11_flgastro2253.indd   53 11/27/2010   3:43:27 PM 11/27/2010   3:43:27 PM54 Frontline Gastroenterology 2011;2:48–56. doi:10.1136/fg.2010.002253
RESEARCH
31 were now using the enzymes for their postprandial 
symptoms (six of whom had previously picked pla-
cebo and three who had withdrawn from the study). 
These 31 patients had been using PEZ for an average 
of 6 months by the time of follow-up. Each of the 
31 current users completed a global symptom severity 
scale of 0 (no problems) to 10 (severe problems) for 
their current postprandial symptoms compared with 
before taking the enzymes. These 31 patients scored 
their baseline severity as 8.6 on the scale of 0–10, but 
after using the enzymes they reported a severity of 
only 2.2. This difference was statistically significant 
(p<0.001).
In addition, these patients were asked to complete 
the formal IBS-QOL survey again. Their responses 
compared with the baseline QOL continued to show 
improvement beyond that recorded at the conclusion 
of the study (table 4).
Discussion
The majority of patients who suffer from postpran-
dial diarrhoea and have pain are considered to have 
IBS-D by the process of exclusion after meeting the 
Rome criteria. However, Hammer and Talley pro-
posed that the validity of the Rome criteria in dis-
criminating IBS from organic disease has not actually 
occurred.43 A recent review of 25 diagnostic studies 
of IBS by Jellema et al also concluded that the symp-
tom based criteria cannot exclude organic disease.44 
Among patients with symptoms suggestive of IBS-D 
or functional diarrhoea, the Mayo Clinic studies 
showed ~45% had evidence of accelerated colonic 
transit.45 46 The cause of the accelerated colonic tran-
sit was assumed to be related to abnormal motility; 
however, the latter may conceivably result from nutri-
ent malabsorption or bile acid malabsorption. In fact, 
Camilleri et al summarised several potential primary 
factors that may induce the symptom phenotype of 
IBS-D or functional diarrhoea, in which transit may 
be aggravated postprandially,47 and in many patients 
symptoms may be worse after meals, as in nutri-
ent malabsorption, gluten intolerance and bile acid 
malabsorption.48 Consequently, treatment options 
have been limited since the underlying aetiology has 
not been established and most patients resort to using 
antimotility agents by default.
This study was spearheaded by the observation that 
the majority of patients with postprandial IBS-D in 
a large internal medicine practice reported a major 
improvement in symptoms when prescribed PEZ to 
use before meals (MEM, personal communication). 
This observation led to the development of the novel 
pilot trial presented in this report.
The study protocol attempted to reproduce the 
clinical benefit reported by requiring each partici-
pant to knowingly attempt to trigger an IBS attack by 
ingesting the foods or substances multiple times that 
they believed caused their symptoms while using the 
blinded drugs. The study design was unfortunately too 
demanding, resulting in a large dropout rate and limit-
ing the statistical findings.
Even in spite of this, 25 patients did choose PEZ com-
pared with 14 for placebo as the effective agent among 
the 39 who completed the study. By intention to treat 
analysis, which includes those patients who dropped 
out, 30/49 (61%) would have chosen enzymes while 
19/49 (39%) would have selected the placebo, trend-
ing towards a definite benefit for enzymes although the 
p value did not reach statistical significance (p=0.078).
On a global symptom score from 0 to 10, patients 
reported a 74% reduction in their perceived postpran-
dial symptoms on the enzymes compared with symptoms 
before starting the study. The enzymes had been used an 
average of 6 months by the time of the final interview in 
2004. We found a significant improvement in the IBS-
QOL scores compared with baseline among these long 
term IBS-D sufferers. Moreover, statistical significance 
was achieved in each IBS-QOL subcategory.
Although there were significant limitations noted 
with this pilot study, including a high dropout rate, 
inability to exclude a first drug effect to account for the 
number of patients choosing PEZ, difficulty measur-
ing the effectiveness of a drug based on specific symp-
toms reduction and the potential inability of patients 
Table 4  Quality of life (QOL) comparison between baseline and 3 month follow-up of trial 
for patients using pancreatic enzymes open label after trial completion
Baseline 3 month follow-up after trial conclusion
QOL parameter Mean N Mean t p Value
Dysphoria 50.60±26.81 31 89.42±10.35 −9.00 0.000
Interference w/activity 44.95±21.96 29 82.27±15.67 −9.32 0.000
Body image 66.59±26.37 29 90.73±10.51 −5.64 0.000
Health worry 64.44±19.57 30 87.50±12.52 −5.99 0.000
Food avoidance 23.61±21.56 30 72.78±21.43 −9.91 0.000
Social reaction 58.27±21.85 31 85.89±11.96 −7.98 0.000
Sexual 73.28±32.86 29 93.53±10.89 −3.76 0.000
Relationships 62.93±26.97 29 92.24±11.77 −7.21 0.000
Overall score 52.65±18.87 25 86.35±9.38 −9.63 0.000
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to identify their triggers accurately or willingness to 
consume the most triggering agent, it did demonstrate 
that there was a trend towards significant reduction of 
IBS-D symptoms with pancreatic enzymes.
The food triggers identified by the patients and the 
rapidity of the postmeal syndrome suggest a possible 
relative disaccharidase deficiency. Scientific evidence 
has demonstrated that the disaccharidase enzymes can 
be downregulated by medications and food substances. 
Quercetin, which is found in multiple foods, including 
onions, is five times more potent than the α-glucosidase 
inhibitor, acarbose.49 50 (Onions were identified by 
43% of the participants as a trigger for the postpran-
dial diarrhoea syndrome.) Research has been extensive 
on locating α-glucosidase inhibitors to treat diabetes 
which have included Vietnamese edible plants51 and 
chamomile tea,52 to name only a few items. Therefore, 
it is possible that the actual food substance that a per-
son is ingesting might result in a transient inhibition of 
the disaccharidases resulting in the digestive disorder 
associated with that meal or patients have a relative 
disaccharidase deficiency. Since α-amylase has been 
shown to potentiate the action of disaccharidases,34 
35 the amylase component or other enzymes in PEZ 
may be ameliorating this effect when taken before the 
ingestion of the triggering substance.
Further studies are needed to study the effectiveness 
of PEZ compared with placebo in patients with this 
condition. In the meantime, however, because PEZ 
are relatively safe, patients might be offered them as a 
therapeutic option if their symptoms occur predomi-
nately after meals.
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